EnfusionENFN
ENFN
About: Enfusion Inc is a software-as-a-service (SaaS) provider focused on transforming the investment management industry. The products and services that comprise its solution are designed to eliminate technology and information barriers, empowering investment managers to confidently make and execute better-informed investment decisions in real time. It simplifies investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth. It generates maximum revenue from the Americas, followed by Asia Pacific and Europe, the Middle East, and Africa.
Employees: 1,143
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
2,122% more call options, than puts
Call options by funds: $1.22M | Put options by funds: $55K
230% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 10
30% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 37
25% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]
21% more funds holding
Funds holding: 109 [Q3] → 132 (+23) [Q4]
9% more capital invested
Capital invested by funds: $863M [Q3] → $939M (+$75.5M) [Q4]
1.03% less ownership
Funds ownership: 97.65% [Q3] → 96.62% (-1.03%) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$11.50
4%
upside
Avg. target
$12.25
11%
upside
High target
$13
17%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
Piper Sandler Sumeet Mody 0 / 0 met price target | 4%upside $11.50 | Neutral Maintained | 23 Dec 2024 |
Stifel Parker Lane 35% 1-year accuracy 17 / 48 met price target | 17%upside $13 | Buy Maintained | 18 Dec 2024 |
Financial journalist opinion
Based on 9 articles about ENFN published over the past 30 days
Negative
Zacks Investment Research
1 week ago
Enfusion, Inc. (ENFN) Lags Q4 Earnings and Revenue Estimates
Enfusion, Inc. (ENFN) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.04 per share a year ago.
Neutral
Business Wire
1 week ago
Enfusion Announces Fourth Quarter and Full Year 2024 Results
NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights: Total revenue was $52.9 million, up 13.9% compared to the same period in the prior year. Gross Profit was $36.5 million with a Gross Profit Margin of 69.0%. Adjusted Gross Profit was $3.
Neutral
Business Wire
2 weeks ago
Clearwater Analytics and Enfusion Announce Expiration of Hart-Scott-Rodino Act Waiting Period For Proposed Acquisition of Enfusion
BOISE, Idaho--(BUSINESS WIRE)--Clearwater Analytics Holdings, Inc. (NYSE: CWAN) (“Clearwater” or the “Company”), a leading worldwide provider of SaaS-based investment management, accounting, reporting, and analytics solutions, and Enfusion, Inc. (NYSE: ENFN) (“Enfusion”), a leader in software-as-a-service solutions for the investment management and hedge fund industry, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR A.
Neutral
Accesswire
2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Enfusion, Inc. (ENFN) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. ("Enfusion") (NYSE:ENFN) and Clearwater Analytics. Investors who purchased Enfusion and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.
Neutral
Business Wire
2 weeks ago
ENFN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Enfusion, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Enfusion, Inc. (NYSE: ENFN) to Clearwater Analytics for $5.85 per share in cash and $5.40 per share in Clearwater Class A Common Stock is fair to Enfusion shareholders. Halper Sadeh encourages Enfusion shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.
Neutral
Accesswire
2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Enfusion, Inc. (ENFN) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. ("Enfusion") (NYSE:ENFN) and Clearwater Analytics. Investors who purchased Enfusion and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.
Neutral
Accesswire
3 weeks ago
Enfusion, Inc. (ENFN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. ("Enfusion") (NYSE:ENFN) and Clearwater Analytics. Investors who purchased Enfusion and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.
Neutral
Accesswire
3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages Enfusion, Inc. (ENFN) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. ("Enfusion") (NYSE:ENFN) and Clearwater Analytics. Investors who purchased Enfusion and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.
Neutral
Accesswire
4 weeks ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Enfusion, Inc. (ENFN) And Encourages Investors to Connect
NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. ("Enfusion") (NYSE:ENFN) and Clearwater Analytics. Investors who purchased Enfusion and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.
Neutral
Accesswire
1 month ago
Bronstein, Gewirtz & Grossman, LLC Encourages Enfusion, Inc. (ENFN) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. ("Enfusion") (NYSE:ENFN) and Clearwater Analytics. Investors who purchased Enfusion and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.
Charts implemented using Lightweight Charts™